All News

A 2-question quiz on the ACIP's recommendations on the new COVID-19 monovalent vaccines that provide protection from currently circulating strains.

Furr on COVID-19 shot: The expectation that 90% of the US population would take this new vaccine that they'd never heard of was probably not practical.

The combination was found equally as effective as 2 standard influenza vaccine comparators and as the Moderna Spikevax COVID-19 booster shot.

Your daily dose of the clinical news you may have missed.

The Novavax COVID-19 vaccine is refreshed with 2023-2024 formula targeting the XBB.1.5 strain.

Many patients with moderate-to-severe asthma may not be using inhaled corticosteroids along with rescue medications to avoid serious disease exacerbations.

Your daily dose of the clinical news you may have missed.

Telehealth use is waning consistently from its peak use during the pandemic, raising the question of what the future holds for virtual care.

The pair of scientists was cited "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19."

Results of a new study showed that greater intake of ultraprocessed foods, particularly artificial sweeteners and artificially sweetened beverages, was linked to a higher risk for depression.

Influenza B is the diagnosis and the patient wants to start antiviral therapy. Factoring in CDC guidance, patient preference, and price, which of the 4 options makes most sense?

Your daily dose of the clinical news you may have missed.

In adults older than age 65 years with T2D, a simple clinical decision support tool plus shared decision making reduced hypoglycemic episodes by half.

Results from a new study of Medicare beneficiaries admitted for an emergency general surgery show the odds of 30-day readmission was 67% lower for those with follow-up visit.

Your daily dose of the clinical news you may have missed.

The addition of ileus as a potential adverse event associated with the GLP-1 mimetic is not the first required for the class by the regulator.

Dupilumab, a monoclonal antibody targeting type 2 inflammation, would be the first treatment of its kind for younger children with eosinophilic esophagitis.

The goal of a PM&R physician is to identify the source of function-limiting pain and then develop the best plan for each patient to return them to their lives.